aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
3.020
-0.110 (-3.51%)
At close: Mar 31, 2025, 4:00 PM
3.050
+0.030 (0.99%)
After-hours: Mar 31, 2025, 6:46 PM EDT
aTyr Pharma Revenue
In the year 2024, aTyr Pharma had annual revenue of $235.00K, down -33.43%.
Revenue (ttm)
$235.00K
Revenue Growth
-33.43%
P/S Ratio
1,155.16
Revenue / Employee
$3,983
Employees
59
Market Cap
268.35M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 235.00K | -118.00K | -33.43% |
Dec 31, 2023 | 353.00K | -10.03M | -96.60% |
Dec 31, 2022 | 10.39M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 10.46M | 10.03M | 2,377.49% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ATYR News
- 4 days ago - aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 days ago - aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise - GlobeNewsWire
- 17 days ago - aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating - Seeking Alpha
- 17 days ago - aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 18 days ago - aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update - GlobeNewsWire
- 19 days ago - aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine - GlobeNewsWire
- 25 days ago - aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis - GlobeNewsWire
- 27 days ago - aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results - GlobeNewsWire